(Q36044573)

11 August 2017

1 reference

title

Pathogen inactivation technology: cleansing the blood supply (English)

1 reference

11 August 2017

Klein HG

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Journal of Internal Medicine

11 August 2017

published in

1 reference

11 August 2017

volume

257

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

224-237

1 reference

Oversight and monitoring of blood safety in the United States

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Monitoring of apheresis platelet bacterial contamination with an automated liquid culture system: a university experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Transmission of West Nile Virus through Blood Transfusion in the United States in 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Screening for viral markers in volunteer and replacement blood donors in West Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Pathogen inactivation of labile blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

An adventure in biotechnology: the development of haemophilia A therapeutics -- from whole-blood transfusion to recombinant DNA to gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Heated clotting factors and seroconversion for human immunodeficiency virus in three hemophilic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Transmission of hepatitis C with pasteurised factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Current status of solvent/detergent-treated frozen plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Nanofiltration of plasma-derived biopharmaceutical products

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Removal of small non-enveloped viruses by nanofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Virus inactivation in blood components by photoactive phenothiazine dyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Use of Deglycerolized Red Blood Cells to Prevent Posttransfusion Infection with Cytomegalovirus in Neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Reducing the Risk for Transfusion-transmitted Cytomegalovirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Inhibition of xenogeneic GVHD by PEN110 treatment of donor human PBMNCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

The effect of exposing murine splenocytes to UVB light, psoralen plus UVA light, or gamma-irradiation on in vitro and in vivo immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Inactivation of infectious pathogens in labile blood components: meeting the challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Inactivation of mycoplasma species in blood by INACTINE PEN110 process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Positively charged porphyrins: a new series of photosensitizers for sterilization of RBCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Binding affinities of commonly employed sensitizers of viral inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Transfusion-associated graft-versus-host disease and its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

Inhibition of murine GVHD by PEN110 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01451.X

10.1111/J.1365-2796.2005.01451.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference